Tonix Pharmaceuticals Holding Corp.
TNXP
$15.52
$0.301.97%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.30M | 9.83M | 10.04M | 10.09M | 11.29M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.30M | 9.83M | 10.04M | 10.09M | 11.29M |
| Cost of Revenue | 6.77M | 6.95M | 7.05M | 7.77M | 8.95M |
| Gross Profit | 3.53M | 2.88M | 2.99M | 2.33M | 2.34M |
| SG&A Expenses | 67.59M | 49.60M | 40.90M | 40.10M | 36.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 110.20M | 92.22M | 82.49M | 87.84M | 93.88M |
| Operating Income | -99.90M | -82.38M | -72.45M | -77.74M | -82.59M |
| Income Before Tax | -99.22M | -81.42M | -131.93M | -130.04M | -135.25M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -99.22 | -81.42 | -131.93 | -130.04 | -135.25 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -99.22M | -81.42M | -131.93M | -130.04M | -135.25M |
| EBIT | -99.90M | -82.38M | -72.45M | -77.74M | -82.59M |
| EBITDA | -97.49M | -79.93M | -69.57M | -74.35M | -78.67M |
| EPS Basic | -20.05 | -39.15 | -1.96K | -2.49K | -4.66K |
| Normalized Basic EPS | -12.31 | -24.25 | -323.87 | -657.14 | -651.04 |
| EPS Diluted | -20.05 | -39.15 | -1.96K | -2.49K | -4.66K |
| Normalized Diluted EPS | -12.31 | -24.25 | -323.87 | -657.14 | -651.04 |
| Average Basic Shares Outstanding | 24.44M | 16.14M | 8.86M | 2.96M | 695.60K |
| Average Diluted Shares Outstanding | 24.44M | 16.14M | 8.86M | 2.96M | 708.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |